The American Journal of Surgery
Volume 199, Issue 2 , Pages 137-143 , February 2010

Differential molecular changes in patients with asymptomatic long-segment Barrett's esophagus treated by antireflux surgery or medical therapy

Received 22 September 2008 ,Revised 21 November 2008

References 

  1. Cameron AJ. Barrett's esophagus: does the incidence of adenocarcinoma matter?. Am J Gastroenterol. 1997;92:193–194
  2. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104:510–513
  3. Provenzale D, Kemp JA, Arora S, et al. A guide for surveillance of patients with Barrett's oesophagua. Am J Gastroenterol. 1994;89:670–801
  4. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;431:405–406
  5. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008;99:836–842
  6. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071
  7. O'Riordan JM, Abdel-Latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257–1264
  8. Duggan SP, Gallagher WM, Fox EJ, et al. Low pH induces co-ordinate regulation of gene expression in oesophageal cells. Carcinogenesis. 2006;27:319–327
  9. Murphy JO, Ravi N, Byrne PJ, et al. Neither antioxidants nor COX-2 inhibition against esophageal inflammation protect against esophageal inflammation in an experimental model of severe reflux. J Surg Res. 2008;142:20–27
  10. Abdel-Latif MM, O'Riordan JM, Ravi N, et al. Activated nuclear factor kappa-B and cytokine profiles in the esophagus parallel tumor regression following neo-adjuvant chemoradiotherapy. Dis Esophagus. 2005;18:246–252
  11. O'Riordan JM, Byrne PJ, Ravi N, et al. Long-term clinical and pathologic response of Barrett's esophagus after anti-reflux surgery. Am J Surg. 2004;188:27–33
  12. Hofstetter WL, Peters JH, De Meester TR, et al. Long-term outcomes of anti-reflux surgery in patients with Barrett's esophagus. Ann Surg. 2001;234:532–538
  13. Rantanen TK, Rasanen JV, Sihvo EIT, et al. The impact of anti-reflux surgery on oxidative stress of esophageal mucosa caused by gastroesophageal reflux disease: 4-yr follow-up study. Am J Gastroenterol. 2006;101:222–228
  14. Wetscher GJ, Hinder RA, Bagchi D, et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg. 1995;170:552–557
  15. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal esophagus (A quantitative measure of gastroesophageal reflux). Am J Gastroenterol. 1974;62:325–332
  16. Rossetti ME, Libermann-Heffert D, Brauner RB. The “Rossetti” modification of the Nissen fundoplication: technique and results. Dis Esophagus. 1996;9:258–262
  17. Comstock GW, Norkus EP, Hoffman SC, et al. Stability of ascorbic acid, carotenoids, retinol, and tocopherols in plasma stored at -70 degrees C for 4 years. Cancer Epidemiol Biomarkers Prev. 1995;4:505–507
  18. Kallner A, Hartmann D, Hornig D. Steady-state turnover and body pool of ascorbic acid in man. Am J Clin Nutr. 1979;32:530–539
  19. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996;93:3704–3709
  20. Madrigal L, Lynch S, Feighery C, et al. Flow cytometric analysis of surface major histocompatibility complex class II expression on human epithelial cells prepared from small intestinal biopsies. J Immunol Methods. 1993;158:207–214
  21. Basu KK, Bale R, West KP, et al. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol. 2002;14:1187–1192
  22. Theisen J, Peters JH, Fein M, et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg. 2005;241:63–68
  23. Chang EY, Morris CD, Seltman AK, et al. The effect of anti-reflux surgery on esophageal carcinogenesis in patients with Barrett's esophagus: a systematic review. Ann Surg. 2007;246:11–21
  24. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–466
  25. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491–500
  26. Oh DS, DeMeester SR, Vallbohmer D, et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg. 2007;142:554–560
  27. Lin SC, Liu CJ, Yeh WI, et al. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:45–47
  28. Kim LH, Shin HD, Park BL, et al. Identification of variants in NFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients. Hum Mutat. 2003;21:652–653
  29. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35–45
  30. Curran JE, Weinstein SR, Griffiths LR. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett. 2002;188:103–107
  31. Huajie BU, Inger R, Xiao-Feng S, et al. Importance of polymorphisms in NF-κB1 and NF-κBIα genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol. 2007;133:859–866
  32. Jaiswal K, Lopez-Guzman C, Souza RF, et al. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol. 2006;290:G335–G342
  33. Mariette C, Piessen G, Leteurtre E, et al. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. Surgery. 2008;143:58–71
  34. Burnat G, Rau T, Elshimi E, et al. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol. 2007;42:1460–1465
  35. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol. 2002;283:G327–G334
  36. Song S, Guha S, Liu K, et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2007;56:1512–1521
  37. Sarela AI, Hick DG, Verbeke CS, et al. Persistent acid and bile reflux in asymptomatic patients with Barrett's esophagus receiving proton pump inhibitor therapy. Arch Surg. 2004;139:547–551
  38. Zhang F, Altorki NK, Wu YC, et al. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology. 2001;121:1391–1399
  39. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331–2338
  40. Wetscher GJ, Gadenstaetter M, Klingler PJ, et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. Ann Surg. 2001;234:627–632
  41. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192:172–181
  42. Lundell L, Miettinen P, Myrvold HE, et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol. 2000;12:879–887
  43. Isolauri J, Luostarinen M, Viljakka M, et al. Long-term comparison of antireflux surgery versus conservative therapy for reflux esophagitis. Ann Surg. 1997;225:295–299
  44. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg. 2003;237:291–298
  45. Rantanen TK, Sihvo EI, Rasanen JV, et al. Gastroesophageal reflux disease as a cause of death is increasing: analysis of fatal cases after medical and surgical treatment. Am J Gastroenterol. 2007;102:246–253
  46. DeMeester TR. Surgical therapy for Barrett's esophagus: prevention, protection and excision. Dis Esophagus. 2002;15:109–116

PII: S0002-9610(09)00057-9

doi: 10.1016/j.amjsurg.2008.11.032

The American Journal of Surgery
Volume 199, Issue 2 , Pages 137-143 , February 2010

Article Tools

* Image Usage & Resolution